Ask the Expert: How Can Genomic Markers Be Used Best to Stratify Which Patients to Treat?

Posted by Gerald L. Andriole, Jr., MD | Oct 2017

Gerald L. Andriole, Jr., MD, Barnes-Jewish Hospital, St. Louis, Missouri, explains the ways to use genomic markers to stratify which patients to treat and which to place on active surveillance.

Interview produced by Prostatepedia

Keywords: genomic markers, risk stratification, active surveillance, prostate cancer

About The Author

Gerald L. Andriole, Jr., MD

Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed his Urology Residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a Fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 35 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial, as well as PI of both the NIDDK Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial and the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Association, the American Association for Cancer Research, the American Society of Clinical Oncology, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Ask the Expert: How Can Genomic Markers Be Used Best to Stratify Which Patients to Treat?

About The Author

Gerald L. Andriole, Jr., MD

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Ask the Expert: How Can Genomic Markers Be Used Best to Stratify Which Patients to Treat?

About The Author

Gerald L. Andriole, Jr., MD

Related Posts

Biomarkers: PSA, 4K, or PHI?

What Role Do Markers Play in Establishing Active Surveillance or Definitive Care?

The Pros and Cons of Genomic Markers for Biopsy Guidance

Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses